Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X‐ray Analysis
L Legnani, D Colombo, S Villa… - European Journal of …, 2012 - Wiley Online Library
Vicriviroc is a piperazine‐based CCR5 receptor antagonist, with better oral availability,
potency, safety, and pharmacological properties than those of its precursor SCH‐C, but …
potency, safety, and pharmacological properties than those of its precursor SCH‐C, but …
Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X-ray Analysis
L Legnani, D Colombo, S Villa, F Meneghetti… - EUROPEAN JOURNAL …, 2012 - iris.unipv.it
Vicriviroc is a piperazine-based CCR5 receptor antagonist, with better oral availability,
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …
Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X-ray Analysis
L Legnani, D Colombo, S Villa, F Meneghetti… - EUROPEAN …, 2012 - boa.unimib.it
Vicriviroc is a piperazine-based CCR5 receptor antagonist, with better oral availability,
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …
Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X‐ray Analysis
L Legnani, D Colombo, S Villa, F Meneghetti… - European Journal of …, 2012 - infona.pl
Vicriviroc is a piperazine‐based CCR5 receptor antagonist, with better oral availability,
potency, safety, and pharmacological properties than those of its precursor SCH‐C, but …
potency, safety, and pharmacological properties than those of its precursor SCH‐C, but …
Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X-ray Analysis
L Legnani, D Colombo, S Villa, F Meneghetti… - EUROPEAN JOURNAL …, 2012 - air.unimi.it
Vicriviroc is a piperazine-based CCR5 receptor antagonist, with better oral availability,
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …
[引用][C] Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X-ray Analysis
L LEGNANI, D COLOMBO, S VILLA… - European journal of …, 2012 - pascal-francis.inist.fr
Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT
Calculations, NMR Spectroscopy, and X-ray Analysis CNRS Inist Pascal-Francis CNRS Pascal …
Calculations, NMR Spectroscopy, and X-ray Analysis CNRS Inist Pascal-Francis CNRS Pascal …
Complete Characterization of the 3D Properties of the CCR5 Antagonist Vicriviroc through DFT Calculations, NMR Spectroscopy, and X-ray Analysis.
L Legnani, D Colombo, S Villa… - … Journal of Organic …, 2012 - search.ebscohost.com
Vicriviroc is a piperazine-based CCR5 receptor antagonist, with better oral availability,
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …
potency, safety, and pharmacological properties than those of its precursor SCH-C, but …